Plexxikon advances first oncology development candidate

Plexxikon Inc. today announced that the company has initiated IND-enabling studies with PLX4032, the company's oncogenic B-Raf inhibitor, a novel, small molecule drug candidate for the treatment of cancer. This compound selectively inhibits the cancer causing form of the B-Raf gene, a mutation found in 70% of skin cancers and a significant number of colorectal, ovarian and thyroid cancers. At the 97th Annual Meeting of the American Association for Cancer Research, Plexxikon scientists presented preclinical data demonstrating that a low dose of this oral V600E B-Raf inhibitor preferentially stopped tumor growth in malignant melanoma and colorectal cancer cells.

In the oral presentation titled "Development of a Novel Inhibitor of Oncogenic B-Raf," (Abstract #2412), Plexxikon scientists report that the company's V600E B-Raf inhibitor showed strong selectivity and potency against specific melanoma and colorectal cell lines. In addition, this compound demonstrated robust efficacy in xenograft models using a once-daily low oral dose, with evidence of tumor shrinkage and prolonged delay of tumor growth for a significant post-dosing period.

"Plexxikon's V600E B-Raf inhibitor may represent the first opportunity to target a disease-specific gene found only in cancerous cells and not in normal cells. With its clean selectivity profile, and specific targeting of tumors, we anticipate this drug candidate will be very safe for patients," said K. Peter Hirth, Ph.D., chief executive officer of Plexxikon Inc. "Plexxikon's advancement of this oncology candidate to development, together with our broad program in diabetes and metabolic disease, further demonstrate the depth and breadth of our novel drug discovery platform. We intend to file an IND (Investigational New Drug) application and initiate Phase 1 clinical trials in the second half of 2006 for our oncogenic B-Raf inhibitor."

Plexxikon's Oncology Programs Driven by Advent of Personalized Medici

Contact: Angela Bitting
AB Corporate Communications

Page: 1 2

Related biology news :

1. Study advances vCJD prion detection
2. New genetic test developed at Emory advances detection and diagnosis of muscular dystrophy
3. SNM advances professional definition for molecular imaging
4. New research advances energy efficiency, safety and performance of public transit
5. InfoSNM highlights advances in computer, information sciences for molecular imaging
6. Mouse model advances understanding of synovial sarcoma
7. Latest advances in DNA sequencing highlighted at DOE Joint Genome Institute User Meeting
8. Study advances evidence for receptors role in alcohol pleasure and problems
9. MIT bioengineer advances survival, promise of adult stem cells
10. AAAS Oceans Panel examines advances in science and technology to boost fishery sustainability
11. Research advances on nanotech workplace health and safety

Post Your Comments:

(Date:5/2/2019)... , ... April 30, 2019 , ... ... LLP is pleased to announce that Gunes Bender, Ph.D., a registered patent ... sciences practice group. In his new role, Bender provides technical support and scientific ...
(Date:4/27/2019)... ... April 26, 2019 , ... Washington State University’s Center for ... than 30 student venture teams, representing nearly 150 students, presented their business ideas ... The top five teams in the College League were awarded prize money with ...
(Date:4/25/2019)... , ... April 24, 2019 , ... ... Services Secretary Alex Azar today, a broad collective of 62 individual scientists, bioethicists, ... American Society of Gene & Cell Therapy (ASGCT), across industry and academia called ...
Breaking Biology News(10 mins):
(Date:4/18/2019)... , ... April 18, 2019 , ... ... a research team that includes a chemical engineer at Worcester Polytechnic Institute (WPI) ... that may make it possible to manufacture isobutanol and other biofuels more economically. ...
(Date:4/12/2019)... (PRWEB) , ... April 12, 2019 , ... ... recent developments in neurotechnology and will educate about innovative tools and devices being ... your local listings for more information. , This segment of Advancements will focus ...
(Date:4/9/2019)... ... April 09, 2019 , ... Sonny Bar Lisa, or Sonny ... for approximately two months. After a series of diagnostics, an MRI was performed ... owner, Alison, researched the injury and found that VetStem Regenerative Cell Therapy ...
(Date:4/8/2019)... ... April 09, 2019 , ... ... innovative non-profit research center Chan Zuckerberg Biohub (CZ Biohub) has chosen Geneious Biologics ... repertoires is part of CZ Biohub’s efforts to establish new approaches to inform ...
Breaking Biology Technology:
Cached News: